午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

Welcome to chemicalbook!
Chinese English Japanese Germany Korea
010-86108875
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook CAS DataBase List Binimetinib
606143-89-9

Binimetinib synthesis

10synthesis methods
Binimetinib, also known as MEK162 (ARRY-162), is an oral, highly selective MEK inhibitor. In preclinical studies, MEK162 showed significant antitumor activities in cell lines and animal models. MEK162 is the first targeted therapy to show activity in patients with NRAS -mutated melanoma and might offer a new option for a cancer with few effective treatments.
Synthetic Routes
  • ROUTE 1
  • Binimetinib synthesis

    Anon. Process for the preparation of 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benz[d]imidazole-6-carboxylic acid. IP.com Journal. Volume 15. Issue 12B. Pages 1pp.Journal; Patent. (2015).

  • ROUTE 2
  • Binimetinib synthesis

    Chen, Jian. Synthetic method of Binimetinib. Assignee Hunan Ouya Biological Co., Ltd., Peop. Rep. China. CN 105820124. (2016).

  • ROUTE 3
  • Binimetinib synthesis

    Huang, Xizhong; Peters, Malte; Schumacher, Karl Maria; Cao, Zhu Alexander; Gansert, Jennifer Lorraine; Chang, David Dong Eun; Beltran, Pedro. Combination therapy. Assignee Novartis Pharma AG, Switz.; Amgen Inc. WO 2013142182. (2013).

  • ROUTE 4
  • Binimetinib synthesis

    Wallace, Eli M.; Lyssikatos, Joseph P.; Marlow, Allison L.; Hurley, T. Brian; Koch, Kevin. Preparation of phenylaminobenzimidazolecarboxylates as mitogen activated protein kinase kinase (MEK) inhibitors. Assignee Array BioPharma, Inc., USA. US 20040116710. (2004).

Binimetinib synthesis

Anon. Process for the preparation of 5-((4-bromo-2-fluorophenyl)amino)-4-fluoro-1-methyl-1H-benz[d]imidazole-6-carboxylic acid. IP.com Journal. Volume 15. Issue 12B. Pages 1pp.Journal; Patent. (2015).

-

Yield:-

Steps:

Multi-step reaction with 5 steps
1: caesium carbonate; tris-(dibenzylideneacetone)dipalladium(0); 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene / toluene; 1,4-dioxane / 8 h / 99 °C / Inert atmosphere
2: potassium trimethylsilonate / N,N-dimethyl-formamide; tetrahydrofuran / 1.67 h / 20 - 25 °C / Inert atmosphere
3: 1,1'-carbonyldiimidazole / tetrahydrofuran / 2 h / 20 - 50 °C
4: N,N-dimethyl-formamide; tetrahydrofuran / 1 h / 50 °C / Inert atmosphere
5: phosphoric acid; water / acetonitrile / 6.25 h / 20 - 53 °C

References:

NOVARTIS AG;ARRAY BIOPHARMA INC.;KRELL, Christoph, Max;MISUN, Marian;NIEDERER, Daniel, Andreas;PACHINGER, Werner, Heinz;WOLF, Marie-christine;ZIMMERMANN, Daniel;LIU, Weidong;STENGEL, Peter, J.;NICHOLS, Paul WO2014/63024, 2014, A1

Binimetinib Related Search: